Couples to enroll in yearlong study of pregnancy prevention; UW School of Medicine is one of 3 U.S. clinical sites
Three U.S. sites are enrolling couples in the first clinical trial to test the safety and efficacy of a gel for men to prevent unintended pregnancy. (Trial subjects’ criteria and investigators’ contact info at clinicaltrials.gov)
Today’s launch was announced jointly by the Population Council, the National Institute of Child Health and Human Development (NICHD), the Los Angeles Biomedical Research Institute and the University of Washington School of Medicine.
The gel being tested is composed of Nestorone® (segesterone acetate), a progestin hormone used for female contraception, and testosterone. NES/T is a novel, reversible contraceptive for men designed to be absorbed through the skin on the upper arms and shoulders.
“The potential of this new gel is huge,” said William Bremner, professor of medicine at the UW School of Medicine and trial director in Seattle. “There is a misperception that men are not interested in, or are even afraid of, tools to control their own fertility. We know that’s not the case.”
[Download video soundbites of Drs. Bremner and Page discussing the trial.]
Previous multinational surveys have shown that more than half of men say they would use a male contraceptive if it is reversible and uncomplicated. Proving efficacy and acceptability is essential to overcoming misperceptions that men aren’t interested in new contraceptive options.
“We hope that results from this trial will help pave the way for renewed interest in male contraceptive development and propel this important public health work forward,” said Stephanie Page, a UW professor of medicine and a study principal investigator.
The NES/T gel trial is sponsored by the NICHD, part of the National Institutes of Health, and co-directed by the Population Council and NICHD. Couples are being recruited throughout the NICHD’s Contraceptive Clinical Trials Network (CCTN). The trial is first launching in Seattle, Los Angeles, and Kansas City (Kansas) and later will include sites in Chile, England, Italy, Kenya, Scotland, and Sweden.
Worldwide, 85 million pregnancies (40 percent of all pregnancies) per year are unplanned, contributing to a higher incidence of adverse health outcomes for women and infants. Apart from condom use, withdrawal during sex, and vasectomy, no other contraceptive options exist for men.
“Expanding male contraceptive options could help make family planning more of a shared responsibility between women and men,” said Regine Sitruk-Ware, distinguished scientist at the Population Council’s nonprofit Center for Biomedical Research and co-director of the trial. “Safe, effective, and reversible tools for men to control their own fertility gives new meaning and significance to the term ‘family planning.’ No matter the challenge, we must continue to innovate and develop new products to improve lives.”
More than 400 couples are anticipated to enroll in the Phase IIb trial, which is the first to test the gel product for contraceptive efficacy, or pregnancy prevention, in the female partner.
“We have been developing this product for more than a decade,” said Diana Blithe, chief of NICHD’s Contraceptive Development Program and director of the CCTN. “We are hopeful that the NES/T gel study will demonstrate effectiveness of a male method for use by couples. A successful result may lead to additional scientific discovery around contraceptive products for men.”
Men and their female partners are active participants in the study. Men will apply the gel once every day. Once the man’s sperm count reaches an appropriate level to prevent pregnancy—a process anticipated to take eight to 16 weeks—the couple will be informed that they should begin to use the gel as their only form of contraception for one year. During this phase, the man’s sperm count will be checked regularly to help minimize the possibility of pregnancy.
The NES/T gel is designed to decrease a man’s sperm production without reducing his sexual drive or enjoyment. The trial will also test the acceptability of the daily gel application as a contraceptive among the participating couples—a critical measure for real-world use.
“The success of a reversible contraceptive for men requires an approach that reduces the production of sperm without impacting a man’s testosterone levels or ability to produce sperm at a later date,” said Christina Wang, Los Angeles Biomedical Research Institute lead researcher and a study principal investigator. “The challenge is achieving the right combination of Nestorone and testosterone at the right time.”
Results from the trial are expected in 2022 and will help determine whether the NES/T gel should be evaluated in a separate, larger-scale Phase III contraceptive efficacy clinical trial, with the aim of obtaining approval from the U.S. Food and Drug Administration to market the product as a male contraceptive.
[Interested couples can find site investigators’ contacts information and selection criteria here.]
Learn more: 1st trial launches to test male contraceptive gel’s efficacy
The Latest on: Male contraceptive
[google_news title=”” keyword=”male contraceptive” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Male contraceptive
- 14 months later, still no word if Iowa AG will cover contraception for rape victimson March 27, 2024 at 5:55 pm
DES MOINES — Republican Iowa Attorney General Brenna Bird's office says an audit of the state's victim services program is delaying a decision on whether the state should continue to reimburse ...
- The “Male IUD” Is Closer Than We Think. Here’s What Experts Want You to Knowon March 27, 2024 at 3:33 pm
A contraception method for those assigned male at birth is closer than you might think, and it could forever shift the way we talk about pregnancy prevention. When biotech company ...
- Male Contraceptive Initiative Marks Women’s History Month With Investment in Birth Control Pill for Menon March 27, 2024 at 6:00 am
Phase 1a study of first hormone-free male pill completes enrollment DURHAM, NC / ACCESSWIRE / March 27, 2024 / Male Contraceptive Initiative has invested $500,000 in YourChoice Therapeutics, a San ...
- Demand for Male Contraceptionon March 25, 2024 at 5:00 pm
2012;12(5):605-613. Acceptability of data from clinical trials improve upon hypothetical surveys in that they are based on real experience with male contraception. However, men who participate in ...
- Prof Chris Barratt: male contraceptive pill enters human trialson March 22, 2024 at 12:58 pm
Women still take most of the responsibility for contraception, but a long anticipated "male pill" could soon become a reality. Several non-hormonal male contraceptive pills that work by slowing sperm ...
- Male birth control research wins audience over at STAT Madness eventon March 22, 2024 at 1:29 am
Male birth control research wins over the audience at a STAT Madness event at #STATBreakthrough. The idea: a compound that stops sperm in its tracks.
- Male birth control research wins audience over at STAT Madness eventon March 21, 2024 at 5:00 pm
Levin, a pharmacology professor at Weill Cornell Medicine, for his team’s work to create a new, on-demand birth control option for men. “I usually am a big skeptic on anything that’s male ...
- New contraceptive in PNG is first of its kind in Pacificon March 20, 2024 at 12:59 pm
A new family planning method is being rolled out in Papua New Guinea, the first of its kind in the Pacific. The new contraceptive, called Sayana Press, enables women to inject themselves with the ...
- What you need to know about over-the-counter birth control and emergency contraception, from how they work to where to buy themon March 20, 2024 at 10:13 am
Along with Opill, the first birth control pill available without a prescription, there are several options for OTC emergency contraception. Here's what to know.
via Bing News